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Abstract
The evolution of antibiotic resistance is influenced by a variety of factors, including the avail-
ability of resistance mutations, and the pleiotropic effects of such mutations. Here, we iso-
late and characterize chromosomal quinolone resistance mutations in E. coli, in order to
gain a systematic understanding of the rate and consequences of resistance to this impor-
tant class of drugs. We isolated over fifty spontaneous resistance mutants on nalidixic acid,
ciprofloxacin, and levofloxacin. This set of mutants includes known resistance mutations in
gyrA, gyrB, and marR, as well as two novel gyrB mutations. We find that, for most mutations,
resistance tends to be higher to nalidixic acid than relative to the other two drugs. Resis-
tance mutations had deleterious impacts on one or more growth parameters, suggesting
that quinolone resistance mutations are generally costly. Our findings suggest that the prev-
alence of specific gyrA alleles amongst clinical isolates are driven by high levels of resis-
tance, at no more cost than other resistance alleles.
Introduction
The increasing prevalence of antimicrobial resistance (AMR) has become an urgent public
health problem worldwide. For example, resistance to ciprofloxacin, the most commonly pur-
chased antimicrobial by hospitals in Canada between 2008–2014 [1], in Escherichia coli rose to
26.7% in 2015 from 21.6% in 2009 [2]. The present AMR crisis has been attributed to the mis-
use and overuse of antibiotics, as well as the scarcity of novel drug development [3–7]. Given
the rapid increase in the prevalence of resistance, an understanding of the principles underly-
ing resistance evolution is vital.
Adaptation, of which the evolution of AMR is a prime example, is driven by the interplay
between mutation, selection, and demographic processes like drift. Mutation determines the
rate at which beneficial variants are introduced into a population, while selection and demog-
raphy govern the fates of these variants. Thus, in understanding the evolution of AMR, we are
interested in both mutation and selection. We expect, for example, that higher mutation rates
will generally lead to a more rapid evolution of resistance. The spread of a given mutation will
then be influenced by its selective consequences, including its effect on resistance, and on its
pleiotropic effects, such as fitness in the absence of antibiotic, and collateral sensitivity or cross
resistance to other antibiotics.
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The rate of mutation to resistance is given by the product of population size (N), overall
mutation rate (μ), and the fraction (f) of mutations that are beneficial (i.e., those that grant
resistance). Thus, resistance mutations will appear more frequently for larger populations, or
for populations with higher mutation rates. Up to a point, this dependence on Nμ leads to an
increase in the rate of adaptation; however, as Nμ approaches 1, a population is no longer lim-
ited by mutational input, but instead by competition between competing mutations (e.g.,
[8,9]).
Relevantly here, the fraction of mutations granting resistance almost certainly differs
between different antibiotics; for some antibiotics, there will be a greater availability of resis-
tance mutations. Variation in the availability of resistance mutations may reflect differences in
the number of genetic loci that can contribute to resistance. For example, resistance to trimeth-
oprim is largely conferred by mutations in a single gene encoding dihydrofolate reductase
(DHFR) [10], while resistance to chloramphenicol and streptomycin can be conferred by
mutations in a number of different genes [10,11]. Moreover, the number of individual muta-
tions conferring resistance may differ between genes: while a wide range of loss-of-function
lesions in the transcriptional regulator marR will grant multi-drug resistance [12], only a hand-
ful of mutations in gyrA confer quinolone resistance [13,14]. Thus, even given equal popula-
tion size and overall mutation rates, we expect different rates of evolution to resistance to
different antibiotics due to differences in the mutational target size.
Once a resistance mutation has arisen, its persistence and spread may be affected by its
pleiotropic effects, including its fitness costs and effects on resistance to other drugs [15–18].
In the presence of antibiotic, a resistant bacterium has a clear advantage compared to suscepti-
ble genotypes. However, in an antibiotic-free environment, a resistance mutation may impose
a burden, for example through reduced growth rates relative to sensitive strains [19–23]. How-
ever, while resistance mutations are often costly, not all resistance mutations bear a cost, and
such cost-free mutations are likely to persist [24–27]. Melnyk et al. (2015) [28] conducted a
meta-analysis including 179 single chromosomal mutations conferring resistance to 16 antibi-
otics from 8 bacterial species. They reported 8 no-cost mutations, with variable costs of resis-
tance depending on antibiotic class and the species assayed.
Increased resistance to one antibiotic may be accompanied by increased cross-resistance to
other antibiotics. Cross-resistance is often observed between members of the same class of
antibiotic. For example, all quinolones target DNA gyrase and Topoisomerase IV, whose sub-
units are encoded by the gyrA/B and parC/E genes, respectively. Resistance to quinolones can
be conferred by point mutations affecting specific portions of GyrA and ParC, known as the
quinolone resistance-determining regions (QRDR) [13,29–31]. Changes at amino acid posi-
tions 83 and 87 of gyrA lead to a significant loss in quinolone susceptibility [32–34]. Moreover,
known resistance mutations in gyrB mutations affect amino acid positions 426 and 464, sites
that interact with the bound quinolone molecule close to the QRDR of GyrA [35–37].
Cross-resistance can also occur between drug classes—for example, marR mutations
selected by quinolones also confer resistance to phenicols, tetracyclines, and rifampicin
[31,38,39]. Mutations in marR, which encodes a negative regulator of the marRAB operon,
render the repressor function inactive, resulting in increased efflux and reduced permeability
[14,40–43]. By contrast, in collateral sensitivity or negative cross-resistance, acquisition of
resistance to one antibiotic may grant sensitivity to other antibiotics. For example, resistance
to aminoglycosides in E. coli can be conferred by electron transport chain mutations that
reduce proton-motive force (PMF). This decrease in PMF negatively affects the activity of
multi-drug efflux pumps, such as AcrAB-TolC, granting hypersensitivity to many other antibi-
otics [44,45].
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Here, we assess mutation rates, levels of resistance, and pleiotropic effects for chromosomal
mutations conferring resistance to different quinolones, in an effort to understand the full set
of parameters contributing to the origin, spread, and persistence of quinolone resistance.
Quinolones were first used clinically in the 1960’s, and have undergone multiple rounds of
development. The first-generation quinolone, nalidixic acid (nal), possesses a limited spectrum
of activity, but fluorination of the core structure generated the so-called 2nd -generation quino-
lones like ciprofloxacin (cip). Further overall structural developments resulted in 3rd-genera-
tion drugs such as levofloxacin (levo). We predict that, while broad mechanisms of resistance
will be shared between quinolones, resistance mutations will differ in their effects towards dif-
ferent antibiotics owing to differences in antibiotic penetration and/or structural
configuration.
Materials and methods
Bacterial strains and media
The E. coli laboratory strain K-12 (MG1655) was used for all experiments. Lysogeny broth
(LB) (10 g/l tryptone, 5 g/l yeast extract, 10 g/l NaCl per litre; Bishop) was used for agar and
broth cultures.
Quinolone susceptibility assays
Minimum inhibitory concentration (MIC) values for the ancestral strain and for antibiotic-
resistant mutants were determined for nalidixic acid, ciprofloxacin and levofloxacin (Sigma-
Aldrich) using a 96 well plate assay. Antibiotic concentrations started at 10μg/ml, 1μg/ml, and
8μg/ml for nal, cip, and levo, respectively, and were diluted in a two-fold series and dispensed
with 125μl/well of LB into 96-well plates. The 96 well plates were incubated overnight at 30 C,
with shaking at 150 rpm. The MIC was defined as the lowest concentration of antibiotic for
which 90% growth inhibition was visibly observed after overnight culture.
Fluctuation analysis and estimation of mutation rates
Mutation rates to resistance were determined using fluctuation assays [46,47]. A single colony
of E. coli MG1655 was grown overnight in liquid LB at 37 C, with shaking at 150 rpm. Fresh
200μl cultures were inoculated with ~100 cells each. Each independent culture was then grown
to saturation overnight. The final number of cells, Nt
, was estimated from plate counts on LB
without antibiotic. Selective plates were supplemented with antibiotics (nal, cip or levo) at a
concentration of 1xMIC or 2xMIC. 30 replicate populations were plated for each antibiotic at
each concentration. The observed number of mutants, r, was then counted for each replicate.
For estimating the number of mutational events m, the MSS maximum-likelihood method
was used [48]. This method is based on a recursive algorithm for estimating the Luria-Del-
bruck distribution for a given number of mutational events [46]. This method is valid over the
entire range of values of m [49,50]. The mutation rate per cell per generation, M, is calculated
as m divided by the total number of bacteria plated on selective plates (Nt) [47,51,52].
PCR amplification and sequencing of candidate genes
Targeted sequencing of the known resistance loci gyrA and marR was carried out in order to
identify potential resistance mutations. To ensure independence, a single mutant colony was
picked from every plate from the fluctuation assay on which there was growth, and inoculated
overnight in LB broth without antibiotic. DNA was then extracted using the EZ-10 spin col-
umn bacterial DNA miniprep kit (Bio Basic) and PCR was used to amplify the QRDR of gyrA
The mutational landscape of quinolone resistance in Escherichia coli
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(Gyrase forward—5’GTAAAACGACGGCCAGTGATGAGCGAC3’, Gyrase reverse—5’CGGTA
CGGTAAGCTTCTTC3’) and the entire marR gene (MarR-forward 5’GTAAAACGACGGCCA
GTGGTCAATTCA3’, MarR reverse—5’TCTGGACATCGTCATACCTC3’). PCR amplicons
were sent to Genome Quebec for Sanger sequencing. Mutations in these particular regions
were compared with the wild type MG1655 strain of E. coli.
Whole-genome sequencing
Whole-genome sequencing was carried out to identify potential resistance mutations in clones
for which mutations were observed in neither gyrA nor marR. Sequencing libraries were pre-
pared using the Nextera XT kit (Illumina), and sequencing was carried out on the MiSeq plat-
form using paired-end 300bp reads. Raw reads were processed using Trimmomatic-0.35 [53],
allowing for a minimum Phred-scaled quality score of 20 for leading and trailing bases, trun-
cating reads once average quality dropped below 20 in a 4bp sliding window, and dropping all
reads of length less than 36. Read quality was assessed using FastQC (https://www.
bioinformatics.babraham.ac.uk/projects/fastqc/).
Reference-based assembly was carried out using Bowtie-2 [54], with E. coli K-12 (MG1655;
NC_00913.2) as the reference genome. SNPs were called using Samtools [55] and SNP effects
were inferred using SNPeff [56].
24-hour growth curve analysis
Fitness in the absence of antibiotic was estimated using 24-hour growth curves for each single
colony isolate. Growth curves were obtained in triplicate in 96-well plates, inoculated at a
1:100 dilution from overnight cultures. OD600 was measured on a Bioteck ELx808 plate reader
every 37 minutes for 24 hours, incubating at 37 C with 30 s of shaking every 5 minutes. Three
growth parameters, lag time, maximum growth rate and optical density at stationary phase
after 24 hours, were estimated using the program GrowthRates [20].
Results and discussion
Estimation of mutation rates
We estimated mutation rates to resistance for each of the three quinolones nal, cip, and levo
using fluctuation assays [46]. The probability of a mutational event per cell per generation was
estimated at 1x and 2x MIC where MIC values were 10 μg/ml, 15 ng/ml, and 31 ng/ml for nal,
cip, and levo, respectively. The number of observed mutants (r) on each of 30 selective plates
was used to estimate mutation rates to nalR, cipR, and levoR, using the MSS maximum likeli-
hood method [50]. At 1x and 2x MIC, mutation rates differed between antibiotics, with lower
rates to nalR than to cipR or levoR (cip>levo>nal), presumably because fewer resistance muta-
tions are available for nal that can grant sufficiently high levels of resistance (Fig 1, Table 1).
Identification of resistance mutations
We obtained a total of 56 spontaneous quinolone resistant mutants from the fluctuation assays
(one from each plate), and identified putative resistance mutations in 50 of these (Table 2).
Targeted sequencing identified 36 gyrA mutants, 9 marR mutants, and 1 double gyrA, marR
mutant. Whole-genome sequencing identified an additional 4 gyrB mutants. We note that
gyrA/gyrB or marR/gyrB double mutants will be undetected by our approach. However, given
that only one gyrA/marR double mutant was detected, the frequency of double mutants is
probably low. In gyrA, mutations were observed at nucleotides encoding amino acid positions
67, 81, 83, and 87 (Fig 2A), consistent with previous findings that the GyrA QRDR spans
The mutational landscape of quinolone resistance in Escherichia coli
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amino acid 67 to 107 [29,57–59]. The most common alterations in the gyrA QRDR region
were S83L (n = 18) and D87G/N/Y (n = 11). These mutations were found in mutants isolated
against all three drugs, presumably because these positions are located within the positively
charged region close to the DNA-enzyme binding site [31]. Amino acids 83 and 87 are located
near the active site of DNA gyrase, along with the tyrosine-122 residue that interacts with the
broken DNA strand following cleavage [59–66]. The α helix-4 region is particularly essential
Fig 1. Spontaneous mutation rate per 108 cells to quinolone resistance among E. coli K-12 (MG1655). Mutation
rates were estimated from 30 independent cultures at 1x and 2x MIC. Error bars represent 95% confidence intervals.
Note that no colonies were obtained at 2xMIC for Nal.
https://doi.org/10.1371/journal.pone.0224650.g001
Table 1. Spontaneous mutation rates to quinolone resistance in E. coli K-12 (MG1655).
Antibiotic Antibiotic
concentration (μg/
ml)
Mutation rate per culture
‘m’
Mutation rate (M) per 108
cells
Upper 95% Confidence
interval
Lower 95% Confidence
interval
Nalidixic acid
(1xMIC)
11.11 0.368 0.76 0.49 0.39
Ciprofloxacin
(1xMIC)
0.015 1.158 2.41 1.06 0.91
Ciprofloxacin
(2xMIC)
0.030 0.293 0.61 0.42 0.33
Levofloxacin
(1xMIC)
0.0312 1.067 2.22 1.01 0.86
Levofloxacin
(2xMIC)
0.0625 0.174 0.36 0.29 0.22
https://doi.org/10.1371/journal.pone.0224650.t001
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to quinolone binding and the substitution to leucine at position 83 makes the vicinity of α
helix-4 of the gyrase less electron rich, crippling gyrase-quinolone binding [33,61,67]. Muta-
tions at position 87 and 81 also perturb the alignment of the α helix-4 structure.
marR mutations were obtained only in levoR isolates. These point, frameshift, and missense
mutations were dispersed throughout the gene, as expected given that the Mar phenotype can
arise from any loss-of-function mutation (Fig 2C). MarR consists of two domains, one N-C
terminal domain and a helix-turn-helix (HTH) DNA binding domain. The closely packed
hydrophobic core and intermolecular hydrogen bonds stabilize the N-terminus (residues 10–
21) of one subunit and the C-terminus (residues 123–144) of the second subunit, holding the
dimer together. Some of the mutations reported in this study belong to the oligomerization
dimer domain of MarR, such as those at positions 10, 27, and 33 of one terminal subunit, and
positions 123 and 126 of the other equivalent subunit. The rest of the MarR protein is linked
via antiparallel helices emerging out from each of the subunits, encompassing the DNA bind-
ing domain (residues 55–100) [12,42]. Mutations at positions 64 and 69 fall in the HTH DNA
Table 2. MIC fold-increase and mutations in gyrA, gyrB and marR among nalR, cipR, and levoR mutants of E. coli K-12 (MG1655).
S.
No.
Antibiotic MIC WT (ug/
ml)
MIC fold
increase of
mutants
Resistance mutation Total number of nalR, cipR and levoR
mutants
Number of gyrA, gyrB and marR
mutants
Nal Cip Levo gyrA gyrB marR
Nalidixic
acid
10 11
1 64 A67S 2
2 256 S83L 6
3 128 D87G 2
4 64 D426N 1
Ciprofloxacin 0.015 24
1 64 G81C/D 3
2 128 S83L 4
3 32 S83W 2
4 64 D87Y/G/
N
7
5 32 H281L 1
6 32 S464Y 1
7 16 L509G 1
Levofloxacin 0.031 21
1 8 G81C 1
2 16 S83L 8
4 8 D87G 1
3 16 D87G R27P 1
5 16 E10stop 1
6 16 L33R 1
7 8 Q42E 1
8 4 L64fs 1
9 16 G69E 1
10 8 T102S 1
11 8 Q117stop 1
12 4 L123S 1
13 8 N126fs 1
https://doi.org/10.1371/journal.pone.0224650.t002
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binding motif. Other mutations reported here at position 42 and 102 residue at α and β sheets
of MarR, which are essential for the interaction between the two antiparallel strands of HTH
DNA binding domain [42].
WGS revealed gyrB mutations in four isolates for which no gyrA or marR mutations were
detected (Fig 2B). H281L, S464F, and L509Q mutations were found in strains isolated on cip,
and a D426N mutation was found in a strain isolated on nal. The GyrB enzyme consists of two
domains, an N-terminal domain (amino acid 2–393) that incorporates the ATPase catalytic
site, and a C-terminal domain (amino acid 394–804) that interacts with GyrA [68,69]. D426N
and S464F have been previously reported to confer quinolone resistance [35,59,64,70,71]. Both
of these mutations are part of the QRDR of GyrB and cause conformational changes in the
structure of the gyrase subunits [37,59]. The gyrB D426N mutation has been reported before
along with a mutation at position L447, both of which provide a neutral vicinity, owing to
their respective opposite charges. Both of these residues are suggested to be part of a quino-
lone-binding pocket [31,35,36,70,72].
Interestingly, the H281L and L509G mutations have not been previously reported to confer
quinolone resistance. These two novel mutations are located outside the GyrB QRDR. Position
281 is located in the transducer region of GyrB, which forms a cavity just large enough to facili-
tate the transfer of the trapped double-stranded DNA through the DNA gate in the presence of
ATP [73,77–79]. Position 509 is within the TOPRIM domain of GyrB, part of the catalytic
DNA cleavage-rejoining complex along with the GyrA winged helix domain [79,80].
Fig 2. The domain structures of Gyrase A, B, and MarR. Mutations obtained in this study are indicated in bold above. Panel A: Arrangement of GyrA. This
subunit of DNA gyrase consists of the breakage-reunion (BRD) domain, and the quinolone resistance determining region (QRDR-A) site. Panel B:
Arrangement of GyrB, with the ATPase, Transducer (221–392), and Toprim (418–533) regions. The QRDR-B is shown within the Toprim domain of GyrB
[73]. Panel C. MarR domain structure, comprising four helices (H) and three ß-sheets (B). H3 and H4 (57–80) are the recognition and DNA binding motifs
containing H-T-H motifs and the ß-sheet winged structure. H1, H5, and H6 are associated with dimerization [42,74–76].
https://doi.org/10.1371/journal.pone.0224650.g002
The mutational landscape of quinolone resistance in Escherichia coli
PLOS ONE | https://doi.org/10.1371/journal.pone.0224650 November 5, 2019 7 / 18
Direct responses to selection
An increase in fitness in the selective environment is referred to as the direct response to selec-
tion; here, the direct response to selection is measured by an increase in MIC towards the drug
on which a mutant was selected. We found substantial variation between drugs in the magni-
tude of the direct response. Mutants isolated on nal showed a stronger direct response to selec-
tion than did mutants isolated on cip or levo, with a mean increase of 256-fold MIC towards
nal. Mutants isolated on cip and levo showed mean increases of 64-fold and 16-fold towards
cip and levo, respectively (Fig 3).
Among resistance mutations, gyrA mutations consistently showed higher levels of resis-
tance than gyrB or marR, regardless of the antibiotic they were isolated on, which impacts the
variation in MIC values significantly (Table 3). Furthermore, within each gene, the level of
resistance varied by mutation. In the case of gyrA, the S83L mutation conferred higher resis-
tance among all the isolates compared to other mutational sites of gyrA (87, 81 or 67). This
suggests that the widespread occurrence of the S83L mutation amongst clinical isolates is due
to the high level of resistance (S1 Fig).
Cross resistance between quinolones
Cross-resistance between quinolones was widespread: all of the resistant mutants isolated on
one quinolone displayed increased resistance, in varying degrees, to the other two quinolones.
Nonetheless, different quinolones were not equally affected by the resistance mutations (Fig
4). Overall, mutants were more resistant towards nal than they were towards cip or levo.
Among cip and levo, mutations showed smaller gains in resistance on levo. Nevertheless, sig-
nificant correlations between levels of resistance for cip and levo (Pearson’s r = 0.64, t = 6.2,
Fig 3. Direct responses to selection. Changes in MIC for resistant mutants towards the drug on which they were
selected: nal (A), cip (B), and levo (C). The boxplot presents the median, first, and third quartiles, with whiskers
showing either the maximum (minimum) value or 1.5 times the interquartile range of the data, whichever is smaller
(larger).
https://doi.org/10.1371/journal.pone.0224650.g003
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P = 8.433e-08), nal and cip (r = 0.47, t = 3.93, P = 0.0002), and nal and levo (r = 0.38,
t = 3.07, P = 0.0032) suggest a closer relationship between the newer quinolones. This varia-
tion in resistance among quinolones can be explained by the intrinsic structural drug differ-
ences between older and newer quinolone classes. Nal is devoid of any cyclic derivatives
whereas cip and levo have substituents at positions C-6, C-7 and C-8, that offer greater spec-
trum/potency of activity. Thus, the modified quinolone substituents likely reduce resistance
levels by increasing the affinity for GyrA, and by stabilizing the quinolone-DNA complex
[33,81–96].
These trends are also evident for specific loci. gyrA mutants showed the highest gain in
resistance (average 128xMIC) on nal in comparison with cip (32xMIC) or levo (16xMIC).
gyrB mutants also displayed a higher increase in resistance to nal (64xMIC), but the same
increase on cip and levo (16xMIC). The novel H281L and L509G mutations gained similar
increases in resistance with cip and levo, at 32xMIC and 16xMIC respectively. On nal, H281L
gained 64xMIC whereas L509G gained similar increase as with cip or levo, i.e. 16xMIC. Mean-
while, marR mutants did not show as high increases in MICs, with increases of 32x, 16x, and
8xMIC on nal, cip, and levo.
Table 3. Two-way analysis of variance (ANOVA) for the effects of antibiotic and gene on levels of resistance.
Factor F-value P-value
Gene 10.00 0.00025�
Antibiotic 39.30 1.34e-10�
Gene�Antibiotic 2.83 0.09
https://doi.org/10.1371/journal.pone.0224650.t003
Fig 4. Cross-resistance between antibiotics. Fold-increase in MIC of resistant mutants isolated on nal (A), cip (B), and levo
(C) against all three antibiotics. The boxplot presents the median, first, and third quartiles, with whiskers showing either the
maximum (minimum) value or 1.5 times the interquartile range of the data, whichever is smaller (larger).
https://doi.org/10.1371/journal.pone.0224650.g004
The mutational landscape of quinolone resistance in Escherichia coli
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Costs of resistance
The persistence of resistance in the absence of antibiotic is determined in part by the fitness
costs associated with resistance mutations [97–99]. No-cost mutations may contribute to the
persistence of resistance mutations in the absence of antibiotic. We measured three fitness
components in the absence of antibiotic for our set of quinolone resistant mutants: maximum
growth rate (Vmax), density at stationary phase (Max OD), and length of lag phase. Resistant
mutants were consistently found to be costly, exhibiting significant differences in Vmax, Max
OD, and lag time compared to their drug-susceptible ancestor MG1655 (Fig 5, Table 4) (S2
Fig). Thus, overall we observe significant costs of resistance for quinolone resistance muta-
tions, consistent with previous studies [92,100–102].
Some studies have reported that mutations granting higher levels of resistance impose
higher costs [28]. However, we fail to find a significant relationship between MIC and any fit-
ness component. No correlations were found between MIC and growth rate (P = 0.42, Ken-
dall’s tau = 0.08), length of lag phase (P = 0.82, tau = 0.02) or cell density (P = 0.12, tau = 0.15)
(Fig 6). We note that gyrA mutations confer no greater costs than other resistance mutations
(gyrB, marR). Moreover, amongst the handful of mutations in gyrA (S83, D87, G81) that can
confer high level resistance [58,63], a few prominent alleles of gyrA tend to be found in E. coli
clinical isolates [24,62,103,104]. That these mutations confer high levels of resistance, but are
no more costly than other gyrA mutations (Fig 6), could help to explain the prevalence of spe-
cific gyrA mutations amongst clinical isolates.
Conclusions and perspectives
Quinolones target DNA gyrase and topoisomerase IV. Resistance against these drugs can be
achieved by target alteration and/or through efflux and permeability associated mutations. We
find that all 50 spontaneous mutants obtained through fluctuation assays were resistant
through mutations in the known resistance conferring genes gyrA, gyrB, and marR. This find-
ing suggests that there are few other quinolone resistance mutations available in E. coli K-12;
this is somewhat surprising, given that selection experiments in P. aeruginosa have identified
novel resistance mutations [105]. We find significant costs of resistance, and differences in the
mutational supply rate among resistant isolates. Notably, we find gyrA mutations conferred
higher resistance, without greater fitness cost, than other mutations. This finding may explain
the prevalence of gyrA mutations in clinical samples. We also find variation in cross-resistance
Fig 5. Costs of resistance of quinolone resistant mutants. The fitness components measured are growth rate, cell
density, and lag time between gyrA, gyrB, and marR resistance mutations. All the fitness components are compared to
control E. coli K-12 (MG1655). The boxplot presents the median, first, and third quartiles, with whiskers showing
either the maximum (minimum) value or 1.5 times the interquartile range of the data, whichever is smaller (larger).
https://doi.org/10.1371/journal.pone.0224650.g005
Table 4. Effects of resistance mutations on growth parameters.
Factor Post hoc (Tukey HSD) comparisons with E. coli K-12 MG1655
Growth rate Length of Cell density at
(OD600/minute) lag time (minutes) stationary phase
(OD600)
Mean P-value Mean P-value Mean P-value
gyrA-MG1655 -0.032 0.0000011 33.4 <2.0e-16 -0.55 <2.0e-16
gyrB-MG1655 -0.033 0.0000191 28.9 <2.0e-16 -0.52 <2.0e-16
marR-MG1655 -0.029 0.0000173 32.3 <2.0e-16 -0.53 <2.0e-16
https://doi.org/10.1371/journal.pone.0224650.t004
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amongst quinolone resistant isolates, implying that different resistance mutations respond dif-
ferently to quinolone variants. Thus, antibiotic variants may have different implications for the
evolution of resistance. Optimally, we should choose an antibiotic for which resistance is
costly, and where single mutations have relatively small effect, as was the case here for
levofloxacin.
Supporting information
S1 Fig. Comparison between mean fold-increase in MIC values for different resistance
mutations in gyrA, gyrB, and marR regions. Resistance mutations isolated as a direct selec-
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